Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 1.42B+9.8% |
| Revenue (ttm) | n/a |
| Net Income | n/a-55.3% |
| EPS | n/a-21.6% |
| Shares Out | 47.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,761.971 |
| Open | 30.62 |
| Previous Close | 30.86 |
| Day's Range | 29.63 - 30.62 |
| 52-Week Range | 23.75 - 52.93 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 67.00(+125.49%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$RAPP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RAPP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RAPP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RAPP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RAPP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RAPP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RAPP
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $48.02M |
| IWMiShares Russell 2000 ETF | $24.85M |
| VXFVanguard Extended Market ETF | $16.20M |
| VTWOVanguard Russell 2000 ETF | $8.57M |
| IWOiShares Russell 2000 Growth ETF | $8.28M |
| IBBiShares Biotechnology ETF | $6.71M |
Estimated from each fund’s disclosed top holdings × AUM
RAPP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RAPP’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score